Vertex Pharmaceuticals Incorporated with ticker code (VRTX) have now 25 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $463.02 and $300.96 and has a mean target at $375.86. Given that the stocks previous close was at $405.07 this now indicates there is a potential downside of -7.2%. The 50 day MA is $362.34 and the 200 day MA is $343.02. The total market capitalization for the company now stands at 104.77B. The stock price is currently at: $406.60 USD
The potential market cap would be $97,218,559,782 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 30.48, revenue per share of $37.49 and a 14.34% return on assets.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
